The UK's major food supplements trade association has joined the local medicines regulator in fighting a pharma player-led High Court legal action to ban glucosamine's right to exist as both a food and a medicine in the UK and potentially other EU markets.

The action has been mounted by the European arm of Chinese company BlueBio (Yantai) Pharmaceuticals, which has a prescription-only medicines registration across the EU's 28 member states for its glucosamine sulphate product, Dolenio.

Glucosamine is also present as a food supplement (albeit without approved EU health claims for the moment), a situation BlueBio wants to change by forcing the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to close down its supplement status in the UK.

Click here to read the full article.